MX2022014113A - Dosificacion y administracion del anticuerpo anti-ctla-4 activable. - Google Patents

Dosificacion y administracion del anticuerpo anti-ctla-4 activable.

Info

Publication number
MX2022014113A
MX2022014113A MX2022014113A MX2022014113A MX2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A MX 2022014113 A MX2022014113 A MX 2022014113A
Authority
MX
Mexico
Prior art keywords
ctla
dosing
antibody
administration
activatable anti
Prior art date
Application number
MX2022014113A
Other languages
English (en)
Spanish (es)
Inventor
Leonard P James
Michelle Brown
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022014113A publication Critical patent/MX2022014113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2022014113A 2020-05-12 2021-05-11 Dosificacion y administracion del anticuerpo anti-ctla-4 activable. MX2022014113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023850P 2020-05-12 2020-05-12
PCT/US2021/031670 WO2021231346A1 (en) 2020-05-12 2021-05-11 Dosing and administration of activatable anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
MX2022014113A true MX2022014113A (es) 2022-12-08

Family

ID=76197648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014113A MX2022014113A (es) 2020-05-12 2021-05-11 Dosificacion y administracion del anticuerpo anti-ctla-4 activable.

Country Status (13)

Country Link
US (1) US20230192856A1 (https=)
EP (1) EP4149544A1 (https=)
JP (1) JP2023526232A (https=)
KR (1) KR20230009432A (https=)
CN (1) CN115515633A (https=)
AR (1) AR122043A1 (https=)
AU (1) AU2021270513A1 (https=)
BR (1) BR112022022713A2 (https=)
CA (1) CA3178649A1 (https=)
IL (1) IL298126A (https=)
MX (1) MX2022014113A (https=)
TW (1) TW202207982A (https=)
WO (1) WO2021231346A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260048119A1 (en) * 2022-08-05 2026-02-19 Bristol-Myers Squibb Company Anti-ctla4 antibodies for treatment of kras mutant cancers

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509274A (pt) * 2004-03-26 2007-09-04 Pfizer Prod Inc usos de anticorpos anti-ctla-4
JP2011509299A (ja) * 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
EP3508215A3 (en) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
JP6595458B2 (ja) * 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
KR20240144452A (ko) * 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20180133313A1 (en) * 2014-12-16 2018-05-17 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
US10983128B2 (en) * 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
JP2018514550A (ja) * 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
SMT202500282T1 (it) * 2015-11-18 2025-09-12 Bristol Myers Squibb Co Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4
US20210206854A1 (en) * 2016-01-27 2021-07-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2019517512A (ja) * 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
CN109475634A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
JP7258747B2 (ja) * 2016-10-28 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法
MY200695A (en) * 2016-11-03 2024-01-11 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
DK3551660T5 (da) * 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
JP2020531430A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗体を標的とする抗ｃｔｌａ４プロボディ療法
CN111247169A (zh) * 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
CA3084370A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020086724A1 (en) * 2018-10-23 2020-04-30 Bristol-Myers Squibb Company Methods of treating tumor
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020198676A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
CN113924118A (zh) * 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
WO2021055994A1 (en) * 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
IL294085A (en) * 2019-12-19 2022-08-01 Bristol Myers Squibb Co Combinations of dgk inhibitors and checkpoint antagonists
KR20220132601A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
EP4097104A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2023164638A1 (en) * 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2025145207A1 (en) * 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Also Published As

Publication number Publication date
KR20230009432A (ko) 2023-01-17
WO2021231346A1 (en) 2021-11-18
CN115515633A (zh) 2022-12-23
BR112022022713A2 (pt) 2023-03-28
US20230192856A1 (en) 2023-06-22
AU2021270513A1 (en) 2023-01-19
JP2023526232A (ja) 2023-06-21
IL298126A (en) 2023-01-01
EP4149544A1 (en) 2023-03-22
CA3178649A1 (en) 2021-11-18
TW202207982A (zh) 2022-03-01
AR122043A1 (es) 2022-08-03

Similar Documents

Publication Publication Date Title
MX2024008677A (es) Conjugados de camptotecina.
PH12020551716A1 (en) Anti-ror antibody constructs
WO2019142149A3 (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
MX2024014607A (es) Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1)
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2018234793A3 (en) Antibodies
WO2017220989A8 (en) ANTI-PD-L1 AND CYTOKINES IL-2
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
ZA202309516B (en) Anti-ccr8 antibodies
PH12021550096A1 (en) Compositions of fcrn antibodies and methods of use thereof
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
ZA202310057B (en) Anti-c-met antibody drug conjugates
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
WO2018081531A3 (en) Methods for human t-cell activation
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2022014113A (es) Dosificacion y administracion del anticuerpo anti-ctla-4 activable.
PH12023550112A1 (en) Anti-notch2 antibodies and methods of use
WO2020128638A8 (en) Flt3 agonist antibodies and uses thereof
EP4257195A3 (en) Anti-cfae antibodies and methods of use
MX2023002705A (es) Combinaciones de lurbinectedina e inhibidor en el punto de control inmunitario.
MX2024013189A (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
MX2025002657A (es) Anticuerpo anti-ilt4 y uso farmaceutico del mismo
MX2024015647A (es) Conjugados farmaco-anticuerpo anti-cd19